"CatSci's purpose is to get new medicines into the hands of patients in need and partnering the game changing siRNA drug development potential at Argonaute is a collaboration we are very excited about. Together we are exploring solutions for the manufacture of high-quality siRNA drug substance to enable robust preclinical studies and at scale for clinical trials."
- Dr Ross Burn (CEO, CatSci)
“Our businesses interact seamlessly to ensure IP generation and business objectives are robust, enforceable and value generating.”
- Rob Docherty PhD EPA MBA (Director, Symbiosis IP)
“At Carbometrics we specialise in the synthesis and bioconjugation of synthetic molecular recognition agents. Our collaboration with Argonaute is an excellent fusion of competencies and an exciting opportunity for us to use our chemistry expertise to augment what is already a paradigm shifting siRNA platform to create revolutionary therapeutics”
- Andy Chapman (CEO and Co-founder, Carbometrics)
Neurofibromatosis
Neurofibromatosis (NF) is a condition that causes tumors to develop along the brainstem and spinal cord. Often times, the tumors that develop in NF patients metastasize and form cancer. NF patients also may experience skin abnormalities such as skin freckling and cafe au lait spots, developmental delays, bone deformities, and vision loss due to tumor growth along the optic nerve.
NF1 is cause by a mutation in one copy of the tumor suppressor gene known as the NF1 gene. This gene controls the production of a protein known as neurofibromin, and when lost, the cell is unable to regulate cell growth. While it is a genetic condition, half of NF cases are not inherited but rather caused by a spontaneous mutation.
There are two types of NF known as neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). Additionally, a third condition sharing many symptoms of NF has been recognized and is known as schwannomatosis. Zac had NF1, the most common type of neurofibromatosis.
Meet the team ↗